Evidence map›Paper›PMID 36393980›Full record

ArticleNature machine intelligence2022

A teachable moment for dual-use.

Fabio Urbina, Filippa Lentzos, Cédric Invernizzi, Sean Ekins

Abstract read
In one paragraph

Article in Nature machine intelligence, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Comparing LDJournal of chemical health & safety · 2023
    Article
  6. Article
  7. Preventing AI From Creating Biochemical Threats.Journal of chemical information and modeling · 2023
    Article
  8. AI in drug discovery: A wake-up call.Drug discovery today · 2023
    Article
  9. Assessing emerging technologies from an arms control perspective.Frontiers in research metrics and analytics · 2022
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Fabio UrbinaCollaborations Pharmaceuticals, Inc., 840 Main Campus Drive, Lab 3510, Raleigh, NC 27606, USA.
Filippa LentzosDepartment of War Studies and Department of Global Health & Social Medicine, King's College London, United Kingdom.
Cédric InvernizziSpiez Laboratory, Federal Department of Defence, Civil Protection and Sports, Switzerland.
Sean EkinsCollaborations Pharmaceuticals, Inc., 840 Main Campus Drive, Lab 3510, Raleigh, NC 27606, USA.

Funding

Centralized assay datasets for modelling support of small drug discovery organizationsR44GM122196 · NIGMS · COLLABORATIONS PHARMACEUTICALS, INC. · PI EKINS, SEAN · 2018 to 2022
$3.3M
MegaTox for analyzing and visualizing data across different screening systemsR43ES031038 · NIEHS · COLLABORATIONS PHARMACEUTICALS, INC. · PI EKINS, SEAN · 2019 to 2020
$349k
Machine learning approaches to predict Acetylcholinesterase inhibitionR43ES033855 · NIEHS · COLLABORATIONS PHARMACEUTICALS, INC. · PI EKINS, SEAN · 2022 to 2022
$256k
NIEHS NIH HHS R43 ES031038NIEHS NIH HHS R43 ES033855NIGMS NIH HHS R44 GM122196
6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Identifiers

PMID36393980
PMCPMC9645784

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.